Evidence map›Paper›PMID 31672839›Full record

ArticleGut2020

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Michael Goggins, Kasper Alexander Overbeek, Randall Brand, Sapna Syngal, Marco Del Chiaro, Detlef K Bartsch, Claudio Bassi, Alfredo Carrato, James Farrell, Elliot K Fishman and 17 more

Erratum issued 2 registry-linked trialsAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 322 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02703545 completednot on this map

International CAPS Registry: Operated Cases and Cases With Advanced Disease Among High-risk Individuals Participating in a Pancreatic Cancer Surveillance Program; a Case-control Study

Typeobservational_patient_registrySponsorJohns Hopkins UniversityRan2014 to 2017Enrolled58ConditionsPancreas Cancer
NCT05006131 recruitingnot on this map

Pancreatic Cancer Screening for At-risk Individuals (The Pancreas Scan Study)

TypeobservationalSponsorBeth Israel Deaconess Medical CenterRan2020 to 2032Enrolled1,395ConditionsPancreatic Cancer, AdultArmsScreening for pancreatic cancer
3 · Its place in the literature

Who cites it

322 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Guideline
  2. Economic evaluations of early detection strategies for pancreatic cancer: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Michael GogginsPathology, Medicine Oncology, Johns Hopkins University, Baltimore, Maryland, USA mgoggins@jhmi.edu.ORCID 0000-0002-4286-2296
Kasper Alexander OverbeekGastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-1829-9963
Randall BrandMedicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Sapna SyngalGI Cancer Genetics and Prevention Program, Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Marco Del ChiaroDepartment of Surgery, Division of Surgical Oncology, Denver, Colorado, USA.
Detlef K BartschDivision of Visceral, Thoracic and Vascular Surgery, University of Marburg, Marburg, Germany.
Claudio BassiDepartment of Surgey, University of Verona, Verona, Italy.
Alfredo CarratoMedical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
James FarrellMedicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Elliot K FishmanThe Russell H Morgan Department of Radiology and Radiological Science, Baltimore, Maryland, USA.
Paul FockensDepartment of Gastroenterology & Hepatology, Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
Thomas M GressGastroenterology, Endocrinology, Metabolism and Infectiology, University of Marburg, Marburg, Germany.ORCID 0000-0002-9333-5461
Jeanin E van HooftGastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
R H HrubanDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Fay KastrinosDivision of Digestive and Liver Diseases, Columbia University Medical Center, New York City, New York, USA.
Allison KleinOncology, Johns Hopkins University, Baltimore, Maryland, USA.
Anne Marie LennonMedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Aimee LucasGastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Walter ParkDivision of Digestive and Liver Diseases, Columbia University Medical Center, New York City, New York, USA.ORCID 0000-0001-8187-4188
Anil RustgiDivision of Digestive and Liver Diseases, Columbia University, New York City, New York, USA.
Diane SimeoneNew York University Medical Center, New York City, New York, USA.
Elena StoffelUniversity of Michigan, Ann Arbor, Michigan, USA.
Hans F A VasenGastroenterology and Hepatology, Leiden University, Leiden, The Netherlands.
Djuna L CahenGastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marcia Irene CantoMedicine, Johns Hopkins University, Baltimore, Maryland, USA.
Marco BrunoGastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
International Cancer of the Pancreas Screening (CAPS) consortium

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
Using markers to improve pancreatic cancer screening and surveillance: a multi-center studyU01CA210170 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael G. Goggins · 2016 to 2026
$9.3M
Using Markers to Improve Pancreatic Cancer ScreeningR01CA176828 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2013 to 2024
$4.1M
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA176828NCI NIH HHS U01 CA210170
6 · The paper itself

Abstract

BACKGROUND AND

aimThe International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals).

methodsA modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed.

resultsConsensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline

conclusionsPancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

Indexed as

Age FactorsBiomedical ResearchCarcinomaEarly Detection of CancerGenetic Predisposition to DiseaseGerm-Line MutationHumansMass ScreeningPancreatic NeoplasmsPopulation SurveillanceRisk Factorsearly detectionfamilial pancreatic cancergenetic predispositionpancreatic ductal adenocarcinomasurveillance

Identifiers

PMID31672839
PMCPMC7295005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.